Reversing cancer
resistance to give patients a fighting chanceClinical trials are a benchmark to test the efficiency and safety of drug therapies throughout the drug design process. As thousands of patients volunteer across all three phases of drug clinical trials, this highly ethical and transparent process helps in the identification of patients’ relevant for treatment, as well as it is crucial for the process that determines a drug’s eligibility for approval by the U.S. Food and Drug Administration (FDA).
At AUM Biosciences, we conduct these clinical studies of our precision therapeutics that have the potential to be more affordable, safe and effective for our patients.
Phase II AUM001 + Keytruda® : Colorectal Cancer
A Study of AUM001 in combination with pembrolizumab in patients with Colorectal Cancer (CRC).
To learn more about this clinical study, kindly visit www.clinicaltrials.gov
Phase II AUM001 + Tecentriq® : Non-Small Cell Lung Cancer & Urothelial Cancer
A Study of AUM001 in combination with Atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC) and Urothelial Cancer.
Phase I AUM601 : Multiple Tumors
A Study of AUM601 in multiple tumors harbouring Pan-TRK mutations.